Inorganic phosphate prevents Erk1/2 and Stat3 activation and improves sensitivity to doxorubicin of MDA-MB-231 breast cancer cells

Molecules

Volumn 20, Issue 9, 2015, Pages 15910-15928

  Sapio, Luigi ^a   Sorvillo, Luca ^a   Illiano, Michela ^a   Chiosi, Emilio ^a   Spina, Annamaria ^a   Naviglio, Silvio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Combination antitumor therapy; Doxorubicin; Erk1 2; Inorganic phosphate; Stat3

Indexed keywords

DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATE; STAT3 PROTEIN;

BREAST TUMOR; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHATES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84947930569     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200915910     Document Type: Article

References (66)

1. Rakha, E.A., Chan, S. Metastatic Triple-negative Breast Cancer. Clin. Oncol. 2011, 23, 587-600.
2. Reaves, D.K., Fagan-Solis, K.D., Dunphy, K., Oliver, S.D., Scott, D.W., Fleming, J.M. The role of lipolysis stimulated lipoprotein receptor in breast cancer and directing breast cancer cell behavior. PLoS ONE 2014, 9, e91747.
3. Santana-Davila, R., Perez, E.A. Treatment options for patients with triple-negative breast cancer. J. Hematol. Oncol. 2010, 3, doi:10.1186/1756-8722-3-42.
4. Pal, S.K., Childs, B.H., Pegram, M. Triple negative breast cancer: Unmet medical needs. Breast Cancer Res. Treat. 2011, 125, 627-636.
5. Mayer, I.A., Abramson, V.G., Lehmann, B.D., Pietenpol, J.A. New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin. Cancer Res. 2014, 20, 782-790.
6. Gutierrez, M.E., Kummar, S., Giaccone, G. Next generation oncology drug development: Opportunities and challenges. Nat. Rev. Clin. Oncol. 2009, 6, 259-265.
7. Lee, J.H., Nan, A. Combination drug delivery approaches in metastatic breast cancer. J. Drug Deliv. 2012, 2012, doi:10.1155/2012/915375.
8. Isakoff, S.J. Triple-negative breast cancer role of specific chemotherapy agents. Cancer J. 2010, 16, 53-61.
9. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L. Anthracyclines: Molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185-229.
10. Chiosi, E., Spina, A., Sorrentino, A., Romano, M., Sorvillo, L., Senatore, G., D'Auria, R., Abbruzzese, A., Caraglia, M., Naviglio, S., et al. Change in TNF-Alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death. J. Interferon Cytokine Res. 2007, 27, 589-597.
11. Carvalho, C., Santos, R.X., Cardoso, S., Correia, S., Oliveira, P.J., Santos, M.S., Moreira, P.I. Doxorubicin: The good, the bad and the ugly effect. Curr. Med. Chem. 2009, 16, 3267-3285.
12. Raina, K., Agarwal, R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: Efficacy and mechanisms. Acta Pharmacol. Sin. 2007, 28, 1466-1475.
13. Vibet, S., Goupille, C., Bougnoux, P., Steghens, J.P., Gore, J., Maheo, K. Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic. Biol. Med. 2008, 44, 1483-1491.
14. Wang, H., Yu, P., Bai, J., Zhang, J., Kong, L., Zhang, F., Du, G., Pei, S., Zhang, L., Jiang, Y., et al. Ocotillol Enhanced the Antitumor Activity of Doxorubicin via p53-Dependent Apoptosis. Evid.-Based Complement. Altern. Med. 2013, 2013, doi:10.1155/2013/468537.
15. Naviglio, S., Della Ragione, F. Naturally occurring molecules and anticancer combination therapies in the era of personalized medicine and economic crisis. Curr. Pharm. Des. 2013, 19, 5325-5326.
16. Takeda, E., Taketani, Y., Sawada, N., Sato, T., Yamamoto, H. The regulation and function of phosphate in the human body. Biofactors 2004, 21, 345-355.
17. Prie, D., Beck, L., Urena, P., Friedlander, G. Recent findings in phosphate homeostasis. Curr. Opin. Nephrol. Hypertens. 2005, 14, 318-324.
18. Khoshniat, S., Bourgine, A., Julien, M., Weiss, P., Guicheux, J., Beck, L. The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals. Cell. Mol. Life Sci. 2011, 68, 205-218.
19. Spina, A., Sapio, L., Esposito, A., di Maiolo, F., Sorvillo, L., Naviglio, S. Inorganic phosphate as a novel signalling molecule with antiproliferative action in MDA-MB-231 breast cancer cells. BioResearch Open Access 2013, 2, 47-54.
20. Rahabi-Layachi, H., Ourouda, R., Boullier, A., Massy, Z.A., Amant, C. Distinct effects of inorganic phosphate on cell cycle and apoptosis in human vascular smooth muscle cells. J. Cell. Physiol. 2015, 230, 347-355.
21. Rendenbach, C., Yorgan, T.A., Heckt, T., Otto, B., Baldauf, C., Jeschke, A., Streichert, T., David, J.P., Amling, M., Schinke, T., et al. Effects of extracellular phosphate on gene expression in murine osteoblasts. Calcif. Tissue Int. 2014, 94, 474-483.
22. Spina, A., Sorvillo, L., di Maiolo, F., Esposito, A., D'Auria, R., di Gesto, D., Chiosi, E., Naviglio, S. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway. J. Cell. Physiol. 2013, 228, 198-206.
23. Camalier, C.E., Young, M.R., Bobe, G., Perella, C.M., Colburn, N.H., Beck, G.R., Jr. Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis. Cancer Prev. Res. 2010, 3, 359-370.
24. Bourgine, A., Beck, L., Khoshniat, S., Wauquier, F., Oliver, L., Hue, E., Alliot-Licht, B., Weiss, P., Guicheux, J., Wittrant, Y. Inorganic phosphate stimulates apoptosis in murine MO6-G3 odontoblast-like cells. Arch. Oral Biol. 2011, 56, 977-983.
25. Spina, A., Sorvillo, L., Esposito, A., Borgia, A., Sapio, L., Naviglio, S. Inorganic Phosphate as a Signaling Molecule: A Potential Strategy in Osteosarcoma Treatment. Curr. Pharm. Des. 2013, 19, 5394-5403.
26. Gewirtz, D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57, 727-741.
27. Gariboldi, M.B., Ravizza, R., Molteni, R., Osella, D., Gabano, E., Monti, E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 2007, 258, 181-188.
28. Taherian, A., Mazoochi, T. Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or Docetaxel. Iran. J. Basic Med. Sci. 2012, 15, 669-677.
29. Tekedereli, I., Alpay, S.N., Tavares, C.D., Cobanoglu, Z.E., Kaoud, T.S., Sahin, I., Sood, A.K., Lopez-Berestein, G., Dalby, K.N., Ozpolat, B. Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer. PLoS ONE 2012, 7, e41171.
30. Varmeh, S., Manfredi, J.J. Overexpression of the dual specificity phosphatase, Cdc25C, confers sensitivity on tumor cells to doxorubicin-induced cell death. Mol. Cancer Ther. 2008, 7, 3789-3799.
31. Naviglio, S., di Gesto, D., Romano, M., Sorrentino, A., Illiano, F., Sorvillo, L., Abbruzzese, A., Marra, M., Caraglia, M., Chiosi, E., et al. Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol. Ther. 2009, 8, 1183-1190.
32. Wang, M.Y., Chen, P.S., Prakash, E., Hsu, H.C., Huang, H.Y., Lin, M.T., Chang, K.J., Kuo, M.L. Connective Tissue Growth Factor Confers Drug Resistance in Breast Cancer through Concomitant Up-regulation of Bcl-xL and cIAP1. Cancer Res. 2009, 69, 3482-3491.
33. Cory, S., Adams, J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2, 647-656.
34. Santen, R.J., Song, R.X., McPherson, R., Kumar, R., Adam, L., Jeng, M.H., Yue, W. The role of mitogen-Activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 2002, 80, 239-256.
35. Haricharan, S., Li, Y. STAT signaling in mammary gland differentiation, cell survival and tumorigenesis. Mol. Cell. Endocrinol. 2014, 382, 560-569.
36. Abrams, S.L., Steelman, L.S., Shelton, J.G., Wong, E.W., Chappell, W.H., Basecke, J., Stivala, F., Donia, M., Nicoletti, F., Libra, M., et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010, 9, 1781-1791.
37. Tentner, A.R., Lee, M.J., Ostheimer, G.J., Samson, L.D., Lauffenburger, D.A., Yaffe, M.B. Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol. Syst. Biol. 2012, 8, doi:10.1038/msb.2012.1.
38. Toniatti, C., Jones, P., Graham, H., Pagliara, B., Draetta, G. Oncology drug discovery: Planning a turnaround. Cancer Discov. 2014, 4, 397-404.
39. Bergsland, E.K. Is More Not Better? Combination Therapies in Colorectal Cancer Treatment. Hematol. Oncol. Clin. N. Am. 2015, 29, 85-116.
40. Anderson, J.J. Potential health concerns of dietary phosphorus: Cancer, obesity, and hypertension. Ann. N. Y. Acad. Sci. 2013, 1301, 1-8.
41. Sabbagh, Y. Phosphate as a sensor and signaling molecule. Clin. Nephrol. 2013, 79, 57-65.
42. Spina, A., Sorvillo, L., Chiosi, E., Esposito, A., di Maiolo, F., Sapio, L., Caraglia, M., Naviglio, S. Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells. Oncol. Rep. 2013, 29, 1689-1696.
43. Cox, R.F., Hernandez-Santana, A., Ramdass, S., McMahon, G., Harmey, J.H., Morgan, M.P. Microcalcifications in breast cancer: Novel insights into the molecular mechanism and functional consequence of mammary mineralisation. Br. J. Cancer 2012, 106, 525-537.
44. Jing, N., Tweardy, D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16, 601-607.
45. Germain, D., Frank, D.A. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res. 2007, 13, 5665-5669.
46. Johnston, P.A., Grandis, J.R. STAT3 signaling: Anticancer strategies and challenges. Mol. Interv. 2011, 11, 18-26.
47. Tan, F.H., Putoczki, T.L., Stylli, S.S., Luwor, R.B. The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy. Curr. Drug Targets 2014, 15, 1341-1353.
48. Liu, A., Liu, Y., Jin, Z., Hu, Q., Lin, L., Jou, D., Yang, J., Xu, Z., Wang, H., Li, C., Lin, J. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS ONE 2012, 7, e46624.
49. Liu, H., Scholz, C., Zang, C., Schefe, J.H., Habbel, P., Regierer, A.C., Schulz, C.O., Possinger, K., Eucker, J. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 2012, 32, 1627-1637.
50. Kulesza, D.W., Carre, T., Chouaib, S., Kaminska, B. Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFα-And NK cytotoxicity. Exp. Cell Res. 2013, 319, 506-516.
51. Spina, A., di Maiolo, F., Esposito, A., D?Auria, R., di Gesto, D., Chiosi, E., Sorvillo, L., Naviglio, S. Integrating leptin and cAMP pathways in triple-negative breast cancer cells. Front. Biosci. (Landmark Ed) 2013, 18, 133-144.
52. Santarpia, L., Lippman, S.M., el-Naggar, A.K. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16, 103-119.
53. Alvarez, R.H., Valero, V., Hortobagyi, G.N. Emerging targeted therapies for breast cancer. J. Clin. Oncol. 2010, 28, 3366-3379.
54. Duffy, M.J., McGowan, P.M., Crown, J. Targeted therapy for triple-negative breast cancer: Where are we? Int. J. Cancer 2012, 131, 2471-2477.
55. Chambard, J.C., Lefloch, R., Pouyssegur, J., Lenormand, P. ERK implication in cell cycle regulation. Biochim. Biophys. Acta 2007, 1773, 1299-1310.
56. Cagnol, S., Chambard, J.C. ERK and cell death: Mechanisms of ERK-induced cell death-Apoptosis, autophagy and senescence. FEBS J. 2010, 277, 2-21.
57. Huang, L., Chen, T., Chen, C., Chen, S., Liu, Y., Wu, J., Shao, Z. Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. World J. Surg. Oncol. 2013, 11, doi:10.1186/1477-7819-11-307.
58. Camirand, A., Fadhil, I., Luco, A.L., Ochietti, B., Kremer, R.B. Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody. Am. J. Cancer Res. 2013, 3, 500-508.
59. Wang, F., Yang, Y. Suppression of the xCT-CD44v antiporter system sensitizes triple negative breast cancer cells to doxorubicin. Breast Cancer Res. Treat. 2014, 147, 203-210.
60. Datta, A., Loo, S.Y., Huang, B., Wong, L., Tan, S.S., Tan, T.Z., Lee, S.C., Thiery, J.P., Lim, Y.C., Yong, W.P., et al. SPHK1 regulates proliferation and survival responses in triple negative breast cancer. Oncotarget 2014, 5, 5920-5933.
61. Duan, Z., Zhang, J., Ye, S., Shen, J., Choy, E., Cote, G., Harmon, D., Mankin, H., Hua, Y., Zhang, Y., et al. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer 2014, 14, doi:10.1186/1471-2407-14-681.
62. Wei, W; Chen, Z.J., Zhang, K.S., Yang, X.L., Wu, Y.M., Chen, X.H., Huang, H.B., Liu, H.L., Cai, S.H., Du, J., et al. The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. Cell Death Dis. 2014, 5, e1428, doi:10.1038/cddis.2014.398.
63. Niu, D., Wang, G., Wang, X. Up-regulation of cyclin E in breast cancer via estrogen receptor pathway. Int. J. Clin. Exp. Med. 2015, 8, 910-915. eCollection 2015.
64. Jun, W., Lin, L., Yurong, C., Juming, Y. Recent advances of calcium phosphate nanoparticles for controlled drug delivery. Mini Rev. Med. Chem. 2013, 13, 1501-1507.
65. Ito, T., Otsuka, M. Application of calcium phosphate as a controlled-release device. Biol. Pharm. Bull. 2013, 36, 1676-1682.
66. Bradford, M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 1976, 72, 248-254.